ArticleClinical cancer research : an official journal of the American Association for Cancer Research2025

A Phase I Dose-Escalation Study of the HIF-2 Alpha Inhibitor DFF332 in Patients with Advanced Clear-Cell Renal Cell Carcinoma.

Sumanta K Pal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.